Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis

Frauke Stascheit1,2 · Ulrike Grittner4,5 · Sarah Hoffmann1,2 · Philipp Mergenthaler1,2,3 · Michael Schroeter6 · Tobias Ruck7 · Mark Pawlitzki7 · Franz Blaes8 · Julia Kaiser9 · Ulrike Schara10 · Adela Della-Marina10 · Andrea Thieme11 · Tim Hagenacker12 · Christian Jacobi13 · Benjamin Berger14,15 · Peter P. Urban16 · Karl Christian Knop17 · Berthold Schalke18 · De-Hyung Lee18 · Petra Kalischewski19 · Heinz Wiendl20 · Andreas Meisel1,2,3

Received: 27 July 2022 / Revised: 16 September 2022 / Accepted: 17 September 2022 / Published online: 27 September 2022
© The Author(s) 2022

Abstract

Background Patients with myasthenia gravis (MG) are potentially prone for a severe COVID-19 course, but there are limited real-world data available on the risk associated with COVID-19 for patients with MG. Here, we investigate whether current immunosuppressive therapy (IST) influences the risk of SARS-CoV-2 infection and COVID-19 severity.

Methods Data from the German myasthenia gravis registry were analyzed from May 2020 until June 2021 and included patient demographics, MG disease duration, comorbidities, current IST use, COVID-19 characteristics, and outcomes. Propensity score matching was employed to match MG patients with IST to those without, and multivariable binary logistic regression models were used to determine associations between IST with (1) symptomatic SARS-CoV-2 infection and (2) severe COVID-19 course, as measured by hospitalization or death.

Results Of 1379 patients with MG, 95 (7%) patients (mean age 58 (standard deviation [SD] 18) presented with COVID-19, of which 76 (80%) received IST at time of infection. 32 patients (34%) were hospitalized due to COVID-19; a total of 11 patients (12%) died. IST was a risk factor for hospitalization or death in the group of COVID-19-affected MG patients (odds ratio [OR] 3.04, 95% confidence interval [CI] = 1.02–9.06, p = 0.046), but current IST was not associated with a higher risk for SARS-CoV-2 infection itself.

Discussion In this national MG cohort study, current IST use was a risk factor for a severe disease course of COVID-19 but not for SARS-CoV-2 infection itself. These data support the consequent implementation of effective strategies to prevent COVID-19 in this high-risk group.

Trial registration information German clinical trial registry (https://www.drks.de), DRKS00024099, first patient enrolled: February 4th, 2019.

Keywords Myasthenia gravis · COVID-19 · Immunosuppressive therapies · Outcome · German myasthenia gravis registry

Introduction

Coronavirus disease 2019 (COVID-19) is a global pandemic and raised concerns about the risk of severe infections in patients with myasthenia gravis (MG) due to several factors, such as preexistent bulbar and respiratory muscle fatigability, exacerbation of symptoms due to infections [16, 28], and an immunocompromised state due to the immunosuppressive therapies (IST) that can be found in up to 80% of patients with MG [33]. There is increasing evidence that patients receiving corticosteroids [17, 49] or rituximab for treatment of different rheumatological [5, 43] and neurological conditions [44, 47] have a higher risk of severe disease courses of COVID-19 than patients without such medications. In addition, many comorbidities associated with a high mortality in COVID-19 [11], such as cardiovascular diseases and type II diabetes, are common among patients with MG [14].

On the other hand, it is well recognized that the severity and outcome of COVID-19 might be associated with the excessive production of pro-inflammatory cytokines [51]
and IST is considered as treatment of choice in patients severely affected by COVID-19 [34]. Thus, the associated risk of COVID-19 severity related to prior IST remains uncertain.

To date, there are limited real-world data on the risk associated with COVID-19 for patients with MG [2, 6, 8, 25, 36, 46]. Management of patients with MG during COVID-19 pandemic has been guided by expert consensus [24]. Apart from a series of case reports [2, 6, 8], the largest studies to date, the international CARE-MG registry [36], and the Czech-MG study [25] reported a mortality of COVID-19 in patients with MG of 24% and 11%, respectively. These data suggest a higher mortality in MG than in the general population with COVID-19 infection, where it is approximately 2% [12, 15, 53]. However, these numbers may be affected by reporting bias, because severe courses are usually hospitalized and therefore easier to capture. This likely has a greater impact when rare diseases are analyzed in small patient populations. Therefore, it is important to understand whether IST is an additional factor favoring the risk of SARS-CoV-2 infection as well as disease severity and poor outcome of COVID-19 in patients with MG. Taking into account known risk factors for severe COVID-19 courses, such as higher age, sex, and comorbidities [15, 53], we here investigated whether patients with MG receiving IST are at higher risk for symptomatic SARS-CoV-2 infection and prone to a worse outcome in case of COVID-19 compared to patients with MG without IST.

Methods

Study design and data collection

This multicenter national cohort study analyzed data from the German Myasthenia gravis Registry (MyaReg), which was established in February 2019 by the national patient support organization for patients with MG (German Myasthenia gravis Society; DMG). MyaReg is assessing longitudinal clinical data on diagnostics, therapy, adverse events, socioeconomic status, and patient-reported outcome parameters of patients with myasthenic syndromes including MG and Lambert–Eaton myasthenic syndrome (LEMS), which were diagnosed based on the current German guidelines [35].

Patients were followed up with entry into the registry in specialized MG clinics on an ongoing basis until June 2021. Socio-demographics (age, sex), MG disease duration, current MG-specific medication, which includes cholinesterase inhibitors, first-line IST (corticosteroids, azathioprine, mycophenolate mofetil, methotrexate, cyclosporine), escalation therapy (rituximab, eculizumab), history of thymectomy, and comorbidities were collected in an electronic database (asthesis®). SARS-CoV-2 infection-related data encompassed COVID-19 severity (hospitalization, stay on intensive care unit, invasive/non-invasive ventilation, myasthenic exacerbation/crisis, exacerbation therapies, change of preexistent IST, antiviral therapy), and outcome (death, rehabilitation, nursing home, discharge to home). Exclusion criteria were missing information on COVID-19 diagnosis (by polymerase chain reaction or antibody testing), MG disease duration, comorbidities, and current MG-specific medication.

Outcome

Endpoints were symptomatic SARS-CoV-2 infection (COVID-19 of any severity) and severity of COVID-19. The severity of COVID-19 course was classified as mild (defined as outpatient treatment), moderate (defined as hospitalization without ICU treatment), and severe (defined as ICU treatment and deceased). We analyzed whether a current IST use was associated with (1) a symptomatic SARS-CoV-2 infection, and (2) with a worse course of COVID-19 defined by hospitalization or death.

Statistical analysis

As descriptive statistics, means and standard deviation (SD) or median and interquartile ranges (IQR) for continuous variables, and absolute and relative frequencies for nominal data were reported. Standardized mean differences (SMD) were calculated as standardized effect sizes. To evaluate the association of IST with the risk of SARS-CoV-2 infection, propensity score matching was employed to match MG patients with IST (exposure) to those without IST. Variables that were used for matching were age, sex, specific diagnosis of myasthenic syndrome, arterial hypertension, thymectomy, heart failure, obesity, chronic obstructive pulmonary disease (COPD), diabetes, and Myasthenia Gravis Foundation of America (MGFA) score. A caliper of 0.2 (of the standard deviation of the logit) was applied [4]. The matching ratio for matching patients with and without IST ranged from 1 to 9, resulting in 203 patients without IST matched to 949 patients with IST. Within the matched subgroup of patients with MG, a multivariable binary logistic regression and a generalized estimation equation (GEE) regression model with adjustment for age, sex, presence of comorbidities, and MGFA clinical classification score was used to analyze the association of IST to risk of infection. Additionally, to evaluate the association of current IST use and COVID-19 severity within the group of COVID-19 patients, SMD were calculated, and multivariable binary logistic regression models adjusted for age, sex and the presence of comorbidities were performed. Patients receiving eculizumab were excluded for risk analysis due to mode of action and the small number.
of subjects treated with eculizumab in our population. Odds ratios (OR) and 95% confidence interval (CI) are reported. Statistical analyses were performed using SPSS (IBM Corp. Released 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp) and R (R Core Team 2020) [50], package MatchIt [18], and the R package geepack [19].

Data availability

All analyzed data are presented in the manuscript and are available on reasonable request from qualified investigators.

Results

Demographics and clinical characteristics

We included 1379 patients with myasthenic syndromes (mean age 59 [SD 18]). Because of missing details on COVID-19 diagnosis, comorbidities, and current MG-specific therapy status, four patients with COVID-19 had to be excluded. Overall, 95 patients with MG and COVID-19 could be included for further analysis, of which the majority was infected with SARS-CoV-2 until March 2021, and only 2% (n = 2) were partly vaccinated against SARS-CoV-2 at the time of infection. MG patients with COVID-19 were comparable to those without COVID-19 regarding age (58 vs. 59 years, SMD: 0.04), sex (41% males vs. 44% males, SMD: 0.05) and disease duration (median 65 vs. 55 months, SMD: 0.13). Atrial fibrillation (11% vs. 5%, SMD: 0.20) and COPD (11% vs. 4%, SMD: 0.24) were more prevalent in MG patients with SARS-CoV-2 infection compared to those without infection. The vast majority of MG patients with and without COVID-19 received IST (80% vs. 84%, SMD: 0.19), of which first-line IST (azathioprine, mycophenolate mofetil, methotrexate, cyclosporine) was the most common (52% vs. 61%), followed by corticosteroid monotherapy (19% vs. 16%) and escalation therapy with rituximab (7.4 vs. 6.7) or eculizumab (2.1% vs. 1.4%). A history of thymectomy was similar in both patient groups (43% vs 40%).

Risk of SARS-CoV-2 infection is not associated with immunosuppressive treatment

To investigate whether a current use of corticosteroid monotherapy, first line, and escalation (only rituximab) IST was associated with SARS-CoV-2 infection, we compared MG patients with and without IST including corticosteroids considering relevant covariates (Table 1). In the group of all MG patients before matching, SARS-CoV-2 infections occurred in 76 of 1167 patients treated with IST (6.5%) compared to 19 of 221 treated without IST (8.6%; Table 1). In the matched subgroup, SARS-CoV-2 infections occurred in 5.1% of patients treated with IST (n = 949 in 203 clusters) compared to 7.9% of those treated without IST (n = 203). A multivariable binary logistic regression model in the nonmatched MG group as well as a GEE model in the matched MG group revealed no substantial association of current IST to the risk of symptomatic SARS-CoV-2 infection (all OR below 1, all 95% CIs included 1; Table 2).

Immunosuppressive treatment is associated with COVID-19 severity

To investigate a potential impact of current IST on the course of COVID-19, we included only the subset of all COVID-19-affected MG patients (n = 95) in the further analysis. Thirty-two (34%) of those MG patients were hospitalized. Twelve (13%) patients were admitted to the ICU, and six of them survived (Table 3). Eight patients required non-invasive ventilation or respiratory support, and ten received invasive ventilation. Myasthenic exacerbation was observed in nine patients, of which five were treated with intravenous immunoglobulins (IVIG), three with plasmapheresis, and one with high-dose corticosteroids (data not shown). Eleven (12%) patients died (Table 3).

Patients hospitalized or deceased compared with non-hospitalized patients were older (68 vs. 53 years, SMD: 0.94), more frequently male (56% vs. 33% males, SMD: 0.47), more severely affected by MG according to MGFA classification score (SMD: 0.83), more frequently receiving MG related IST (84.4% vs. 77.8%, SMD: 0.48) and had a higher prevalence of comorbidities (88% vs. 73%, SMD: 0.37). Several known risk factors for poor outcome after COVID-19 were more frequent in the group of hospitalized or deceased patients compared with the group of non-hospitalized patients: arterial hypertension (50% vs. 33%, SMD: 0.34), COPD (25% vs. 3%, SMD: 0.66), and cancer (19% vs. 6%, SMD: 0.38). A history of thymectomy (36% vs 47%; SMD: 0.23) was less frequently present in patients who were hospitalized or deceased. Disease duration (median 65 vs. 64 months, SMD: 0.11) was similar in both groups. Patients with MG who died due to COVID-19 where more likely to be older with 76 (SD 11) vs. 53 (SD 18) years and more likely to be male (55% vs. 33%) compared to non-hospitalized MG patients with COVID-19. All deceased patients had at least one concomitant disease, with arterial hypertension (n = 6) and type two diabetes type II (n = 4) being the most common. The majority of these patients had MG-specific IST at time of infection (n = 9), of whom 2 received rituximab (Table 3).

After pooling rituximab-treated patients (n = 7) with first-line IST due to the low case number of this subgroup, multivariable binary logistic regression adjusted for age, sex, and comorbidities showed that SARS-CoV-2-infected patients with MG and current IST had a higher risk for
hospitalization or death in comparison to patients without IST or only corticosteroid use (OR 3.04, 95% CI 1.02–9.06, \( p = 0.046 \); Table 4, Model 2). Age was an independent additional risk factor for COVID-19 severity in both models (OR 1.8, 95% CI 1.22–2.64, respectively, OR 1.76, 95% CI 1.21–2.56, \( p = 0.003 \)).

Table 1 Characteristics of patients with myasthenia gravis and with or without immunosuppressive therapy before and after propensity score matching

| Patients with IST | Patients without IST | SMD | Matched patients with IST* | Matched patients without IST | SMD |
|-------------------|----------------------|-----|----------------------------|----------------------------|-----|
| n                 | 1164                 | 215 | 0.28                       | 949 patients in 203 clusters | 0.02|
| Sex male, n (%)   | 531 (45.5%)          | 71  (32.1%) | 0.02                       | 66.6 (32.8%) | 0.02|
| Age in years, mean (SD) diagnosis | 59 (18)                    | 56 (19)                  | 0.02                       | 57 (10)                    | 0.02|
| MG                | 1145 (98.4%)         | 208 (96.7%) | 0.23                       | 196.3 (96.7%) | 0.02|
| LEMS              | 19 (1.6%)            | 7 (3.3%)                  | 0.02                       | 5.9 (2.9%)                  | 0.02|
| Disease duration in months, median (IQR) (34 missing’s) | 59 (23–123)                  | 42 (10–133)             | 0.05                       | 79 (55–132)                  | 0.02|
| Thymectomy, n (%) (4 missing’s) | 473 (40.7%)                  | 79 (35.7%)               | 0.10                       | 82.0 (40.4%)                  | 0.05|
| MGFA (13 missing’s) | 64 (5.5%)                    | 3 (1.4%)                  | 0.53                       | 1.6 (0.8%)                  | 0.05|
| Comorbidities present, n (%) (2 missing’s) | 945 (81.0%)                  | 181(81.9%)                | 0.02                       | 162.0 (79.8%)                | 0.06|
| Autoimmune disease, n (%) | 273 (23.4%)                  | 50 (22.6%)                 | 0.02                       | 52.8 (26.0%)                 | 0.11|
| Diabetes mellitus type II, n (%) | 154 (13.2%)                  | 28 (12.7%)                 | 0.02                       | 24.6 (12.1%)                 | 0.03|
| Arterial hypertension, n (%) | 413 (35.4%)                  | 73 (33.0%)                 | 0.05                       | 65.4 (32.2%)                 | 0.07|
| Heart failure, n (%) | 23 (2.0%)                    | 1 (0.5%)                  | 0.14                       | 1.2 (0.6%)                  | 0.02|
| Atrial fibrillation, n (%) | 67 (5.7%)                    | 10 (4.5%)                  | 0.06                       | 9.3 (4.6%)                  | 0.02|
| Obesity, n (%) | 24 (2.1%)            | 5 (2.3%)                  | 0.01                       | 3.9 (1.9%)                  | 0.01|
| COPD, n (%) | 62 (5.3%)            | 3 (1.4%)                  | 0.22                       | 4.1 (2.0%)                  | 0.05|
| Asthma, n (%) | 119 (10.2%)         | 28 (12.7%)                 | 0.08                       | 23.3 (11.5%)                 | 0.07|
| Cancer, n (%) | 123 (10.5%)         | 22 (10.0%)                 | 0.02                       | 19.7 (9.7%)                 | 0.05|
| Stroke, n (%) | 34 (2.9%)            | 7 (3.2%)                  | 0.01                       | 5.9 (2.9%)                  | 0.04|
| Dementia, n (%) | 6 (0.5%)            | 1 (0.5%)                  | < 0.01                     | 0.8 (0.4%)                  | 0.02|
| SARS-CoV-2 infection | 76 (6.5%)                    | 19 (8.6%)                  | 0.08                       | 10.4 (5.1%)                 | 0.13|

Data are presented as mean (SD), n (%) or median (IQR) showing differences in numbers and characteristics of MG patients with or without immunosuppressive therapy (IST) before and after propensity score matching and were compared by standardized mean differences (SMD). Variables used for matching were age, diagnosis, thymectomy, presence of autoimmune disease, diabetes, arterial hypertension, heart failure, atrial fibrillation, obesity, chronic obstructive lung disease (COPD), asthma, cancer, stroke, and dementia. For COPD and atrial fibrillation exact matching was used. For age, a caliper of 0.5 was chosen. Disease duration is the time from diagnosis until examination date.

Abbreviations: COPD chronic obstructive pulmonary disease, LEMS Lambert–Eaton-Myasthenic Syndrome, IST immunosuppressive therapy, IQR interquartile range, MG myasthenia gravis, MGFA Myasthenia gravis foundation of America classification, n number of included patients, SD standard deviation, SMD standardized mean differences

*Based on average measures on cluster level

**Based on log-transformed values

Discussion

To our knowledge, this study is to date the largest to evaluate the risk of COVID-19 in MG patients in regard to current IST use with an appropriate control group of uninfected MG patients. We identified current IST use not to be a substantial
risk factor for SARS-CoV-2 infection. However, IST, including first line and escalation therapy, was a risk factor for poor COVID-19 prognosis with a higher likelihood of hospitalization and death. Corticosteroid therapy alone was not a relevant risk factor for COVID-19 severity, which is in contrast to other studies examining the impact of IST in MG for outcome after COVID-19 [25, 36, 46]. However, our data indicate that known risk factors for severe COVID-19, such as patient age [11], have a greater impact on the severity of COVID-19 in MG patients than does IST.

Although data on COVID-19 and MG are still scarce, experts agreed early in the pandemic that caution was needed in patients with MG [16, 28, 38]. First, there is the risk of exacerbation of myasthenic symptoms from SARS-CoV-2 infection, compounded by the potentially higher risk of severe courses of COVID-19 due to the immunocompromised state from IST. Approximately 80% of patients with MG receive IST [33], which is in line with our data. Second, discontinuation of IST in patients with MG would likely lead to worsening of myasthenic symptoms. Our data suggest that IST is not per se associated with a higher risk of SARS-CoV-2 infection. This might be due to MG patients with IST being more concerned about COVID-19 than MG patients without IST leading to better compliance with hygiene recommendations in Germany during the study period (e.g., lockdowns, social distancing rules) [26, 31].

Nevertheless, expert consensus agreed that especially MG patients receiving rituximab were more prone to worse COVID-19 outcome [24], as there was evidence of higher risk for hospitalization and mortality in patients with rheumatoid arthritis (RA) [13] or multiple sclerosis (MS) [47] receiving anti-CD20 therapy, which has now been confirmed by large meta-analysis studies [40, 42]. Rituximab treatment is often required long term in MG and may then be associated with a higher risk of severe infections, as recently shown in a Swedish cohort study of MS patients compared with other IST [32]. In our population, seven COVID-19 affected patients received rituximab therapy prior to their infection, of which two patients died. While the association between rituximab therapy and severe outcome is not pronounced in our study (OR 2.35; 95% CI 0.29–19.08), the Czech-MG-COVID-19 study revealed a poor outcome after COVID-19 with three deaths in four MG patients treated with rituximab (OR 35.14; 95% CI 3.2–383.9) [25].

|                  | Non-matched MG patients (n=1352) | Matched MG patients (n=203) |
|------------------|---------------------------------|-----------------------------|
|                  | Nagelkerke $R^2=0.02$            | Marginal $R^2=0.01$         |
|                  | OR (95% CI) for COVID-19 infection | OR (95% CI) for COVID-19 infection |
|                  | $p$                             | $p$                         |
| No corticosteroids and no immune suppression (reference) | 1                             | 1                           |
| Only corticosteroids                                  | 0.82 (0.41–1.66) | 0.589 | 0.74 (0.35–1.60) | 0.445 |
| First line IST (AZT, MMF, MTX, CSA)                   | 0.56 (0.31–1.01) | 0.052 | 0.60 (0.32–1.12) | 0.107 |
| Escalation therapy with rituximab                      | 0.59 (0.23–1.56) | 0.289 | 0.85 (0.29–2.51) | 0.769 |
| Age in decades                                          | 1.00 (0.99–1.02) | 0.692 | –                 | –       |
| Sex male, ref: female                                  | 1.10 (0.68–2.09) | 0.541 | –                 | –       |
| Comorbidities present, ref: no comorbidities present   | 1.19 (0.68–2.09) | 0.541 | –                 | –       |
| MGFA, ref: 0                                           |                               |                             |
| I                                                          | 0.39 (0.16–0.97) | 0.043 | –                 | –       |
| II A                                                      | 0.53 (0.22–1.25) | 0.146 | –                 | –       |
| II B                                                      | 0.50 (0.21–1.18) | 0.112 | –                 | –       |
| III A                                                     | 0.80 (0.28–2.28) | 0.672 | –                 | –       |
| III B                                                     | 0.70 (0.25–1.94) | 0.491 | –                 | –       |
| IV A/IV B/V                                              | 1.10 (0.36–3.33) | 0.868 | –                 | –       |

Odds ratios (OR) and 95% confidence interval (CI) for SARS-CoV-2-infected myasthenia gravis (MG) patients from multivariable binary logistic regression (left side) adjusted for age, sex, MGFA score, and thymectomy status ($n=1352$, Nagelkerke R Square: 0.02), and from generalized estimation equation (GEE) binary logistic regression model (right side) after propensity score matching ($n=203$ matched groups, 936 individuals) without further adjustment

Abbreviations: AZT azathioprine, CI confidence interval, CSA cyclosporine A, GEE generalized estimation equation, IST immunosuppressive therapy, MG myasthenia gravis, MGFA Myasthenia gravis foundation of America classification, MMF mycophenolate mofetil, MTX methotrexate, $n$ number of included patients, OR odds ratio

*Patients treated with eculizumab ($n=20$) or missing covariate data ($n=16$) were excluded from matched and non-matched analysis

Table 2 Multivariable binary logistic regression model in total and generalized estimation equation binary logistic regression model in matched myasthenia gravis patients for SARS-CoV-2 infection with regard to immunosuppression status.
Table 3  Characteristics of myasthenia gravis patients with COVID-19

|                          | Non-hospitalized patients | Hospitalized and/or deceased patients | SMD | Hospitalized patients (survivors, no intensive care) | Patients with intensive care (survivors) | Deceased patients |
|--------------------------|---------------------------|--------------------------------------|-----|-----------------------------------------------------|----------------------------------------|-------------------|
| n                        | 63                        | 32                                   | 15  | 6                                                   | 6 (66.7%)                             | 11                |
| Sex male, n (%)          | 21 (33.3%)                | 18 (56.3%)                           | 0.47| 8 (53.3%)                                           | 4 (66.7%)                             | 6 (54.5%)         |
| Age in years, mean (SD)  | 53 (18)                   | 68 (15)                              | 0.94| 63 (13)                                             | 66 (21)                                | 76 (11)           |
| Disease duration in months, median (IQR) (3 missing's) | 64 (26–123) | 65 (29–163) | 0.11<sup>a</sup> | 51 (27–232) | 31 (7–111) | 109 (47–160) |
| Thymectomy, n (%) (4 missing's) | 28 of 60 (46.7%) | 11 of 31 (35.5%) | 0.23 | 8 (53.3%) | 2 (33.3%) | 1 (10.0%) |
| MGFA                     |                           |                                      |     |                                                     |                                        |                   |
| 0                        | 4 (6.3%)                  | 4 (12.5%)                            | 2 (13.3%) | 1 (16.7%) | 1 (9.1%) |
| I                        | 12 (19.0%)                | 3 (9.4%)                             | 1 (6.7%) | – | 2 (18.2%) |
| II A                     | 15 (23.8%)                | 8 (25.0%)                            | 6 (40.0%) | – | 2 (18.2%) |
| II B                     | 17 (27.0%)                | 5 (15.6%)                            | 3 (20.0%) | 2 (33.3%) | – |
| III A                    | 8 (12.7%)                 | 1 (3.1%)                             | – | – | 1 (9.1%) |
| III B                    | 5 (7.9%)                  | 4 (12.5%)                            | 1 (6.7%) | 3 (50.0%) | – |
| IV A/IV B/V              | 2 (3.2%)                  | 7 (21.9%)                            | 2 (13.3%) | – | 5 (45.5%) |
| Comorbidities present, n (%) | 46 (73.0%) | 28 (87.5%) | 0.37 | 12 (80.0%) | 5 (83.3%) | 11 (100.0%) |
| Autoimmune disease, n (%) | 14 (22.2%) | 5 (15.6%) | 0.17 | 2 (13.3%) | 1 (16.7%) | 2 (18.2%) |
| Diabetes type II, n (%)  | 5 (7.9%)                  | 5 (15.6%)                            | 0.24 | – | 1 (16.7%) | 4 (36.4%) |
| Arterial hypertension, n (%) | 21 (33.3%) | 16 (50.0%) | 0.34 | 6 (40.0%) | 4 (66.7%) | 6 (54.5%) |
| Heart failure, n (%)     | –                        | 3 (9.4%)                             | 0.46 | 2 (13.3%) | – | 1 (9.1%) |
| Atrial fibrillation, n (%) | 6 (9.5%)                | 4 (12.5%)                            | 0.10 | – | – | 4 (36.4%) |
| Obesity, n (%)           | 1 (1.6%)                  | 3 (9.4%)                             | 0.35 | 1 (6.7%) | 1 (16.7%) | 1 (9.1%) |
| COPD, n (%)              | 2 (3.2%)                  | 8 (25.0%)                            | 0.66 | 3 (20.0%) | 2 (33.3%) | 3 (27.3%) |
| Asthma, n (%)            | 9 (14.3%)                 | 2 (6.3%)                             | 0.27 | 1 (6.7%) | – | 1 (9.1%) |
| Cancer, n (%)            | 4 (6.3%)                  | 6 (18.8%)                            | 0.38 | 4 (26.7%) | – | 2 (18.2%) |
| Stroke, n (%)            | 1 (1.6%)                  | 2 (6.3%)                             | 0.24 | 1 (6.7%) | 1 (16.7%) | – |
| Dementia, n (%)          | –                        | 2 (6.3%)                             | 0.37 | – | 1 (16.7%) | 1 (9.1%) |
| Current MG-specific IST  |                           |                                      |     |                                                     |                                        |                   |
| No immune suppression, n (%) | 14 (22.2%) | 5 (15.6%) | 0.17 | 2 (13.3%) | 1 (16.7%) | 2 (18.2%) |
| Only steroids, n (%)     | 15 (23.8%)                | 3 (9.4%)                             | – | 1 (16.7%) | 2 (18.2%) |
| Standard IST (AZT, MMF, MTX, CSA), n (%) | 29 (46.0%) | 20 (62.5%) | 11 (73.3%) | 4 (66.7%) | 5 (45.5%) |
| Escalation therapy       |                           |                                      |     |                                                     |                                        |                   |
| Rituximab, n (%)         | 4 (6.3%)                  | 3 (9.4%)                             | 1 (6.7%) | – | 2 (18.2%) |
| Eculizumab, n (%)        | 1 (1.6%)                  | 1 (3.1%)                             | 1 (6.7%) | – | – | – |

Data are presented as mean (SD), n (%) or median (IQR) showing standardized mean differences (SDM) of hospitalized versus non-hospitalized MG patients with COVID-19 and clinical characteristics of hospitalized and deceased patients. 

Abbreviations: AZT azathioprine, COPD chronic obstructive pulmonary disease, CSA cyclosporine A, IST immunosuppressive therapy, IQR interquartile range, MG myasthenia gravis, MGFA Myasthenia Gravis Foundation of America classification, MMF mycophenolate mofetil, MTX methotrexate, n number of included patients, SD standard deviation, SDM standardized mean differences

<sup>a</sup> based on log-transformed data
Additionally, they found that long-term use of corticosteroids, especially at high dosages, together with rituximab and older age was associated with severity of COVID-19 progression [25], which is also observed in other autoimmune diseases such as RA [13] or MS [47]. In CARE-MG, no information about rituximab therapy was reported; however, of the 91 hospitalized patients, 89% had received IST [36].

The role of corticosteroids as a risk factor of SARS-CoV-2 infection is uncertain, as systemically administered corticosteroids are effective in reducing COVID-19 mortality and are particularly beneficial during acute respiratory distress syndrome (ARDS) [48]. However, corticosteroids may prolong viremia [22] in early COVID-19 stages, which could explain the higher proportion of hospitalized patients with ongoing corticosteroid treatment. It is important to emphasize that we also identified IST including first-line IST due to the low case number (n = 7).

The major limitation of previously published studies on COVID-19 in patients with MG is the lack of an uninfected control group. In addition, there seems to be a reporting bias towards severe cases in previous studies, as the CARE-MG study preliminarily found a mortality rate of 24% [36], which compares with 11% in the Czech-MG study [25], 12%

### Table 4

| Model 1 | Model 2 |
|---------|---------|
| Resource | Resource |
| N=93, Nagelkerke | N=93, Nagelkerke |
| R²=0.30 | R²=0.29 |
| OR (95% CI) for hospitalization or death | OR (95% CI) for hospitalization or death |

| No IST or only corticosteroids (reference) | 1 | First line IST (AZT, MMF, MTX, CSA) | 2.86 (0.94–8.73) 0.064 |
| Escalation therapy (rituximab) | 5.03 (0.72–35.01) 0.103 |
| Age in decades | 1.80 (1.22–2.64) 0.003 |
| Sex male, ref: female | 1.43 (0.50–4.04) 0.506 |
| Comorbidities present, ref: no comorbidities present | 0.85 (0.19–3.86) 0.835 |

Odds ratios (OR) and 95% confidence interval (CI) for hospitalization and death within the group of COVID-19 patients. Multivariable binary logistic regression models were calculated adjusted for age, sex and the presence of comorbidities. Patients treated with eculizumab were excluded from this analysis due to mode of action. In model 2 patients receiving rituximab were included to patients receiving first-line IST due to the low case number (n = 7).

Abbreviations: AZT azathioprine, CI confidence interval, CSA cyclosporine A, IST immunosuppressive therapy, MMF mycophenolate mofetil, MTX methotrexate, OR odds ratio

[41] has been approved for treatment of severe COVID-19. The C5 complement inhibitor eculizumab also shows beneficial effects in patients with severe COVID-19 [3, 9]. Eculizumab is effective and approved in refractory generalized acetylcholine receptor antibody-positive MG [21], and therefore, it might be considered a potentially beneficial treatment option for patients with MG with severe COVID-19, which is why we have not included this patient group in our risk analyses. Although IVIG and therapeutic plasma exchange have no significant benefit on outcome of patients with COVID-19 [29, 45], due to its proven effect in myasthenic crises or exacerbation [38], IVIG and therapeutic plasma exchange [10, 23, 39] should be considered a first-line treatment choice in patients with MG exacerbation in the course of COVID-19 [24, 27].

Data on the role of thymectomy for COVID-19 disease course in MG are scarce. In a systematic review of case series and cases, 5% of patients with a history of thymectomy died, whereas 17% of patients without a history of thymectomy died [1]. Also in our cohort, the proportion of patients who were hospitalized or died was lower with thymectomy in the history than without thymectomy (36% versus 47%). However, this may be biased by age, as patients with late MG do not undergo thymectomy.
in a systematic review [1], and 12% in our study. These differences could be due to various standards of care in the countries from which the CARE-MG data are collected. Nevertheless, the COVID-19-related mortality rate of patients with MG is significantly higher compared to other autoimmune diseases such as RA [13] and MS [47], suggesting that not only IST but also MG-specific characteristics, e.g., exacerbation of myasthenic symptoms/myasthenic crisis due to COVID-19 might influence the outcome. In our study population, 10% of COVID-19-affected patients with MG suffered from exacerbation of myasthenic symptoms, which is comparable with the Czech-MG study [25], but less than in CARE-MG with a rate of 40% [36] and the systematic review with 19% [1]. One COVID-19 patient in our cohort died during the course of a myasthenic crisis, which is within the expected range of a 10% in-hospital mortality for myasthenic crises in Germany [37, 39].

Limitations

Our results obtained in German patients with MG may not be representative for other countries, because SARS-CoV-2 infection and COVID-19 may have varying effects worldwide due to different health care systems. Moreover, the data presented here are based on patients enrolled in a registry and therefore do not cover all COVID-19 affected patients with MG in Germany. Patients who were not treated at a specialized MG center may have a different risk regarding the course of a SARS-CoV-2 infection. However, baseline characteristics about age, disease duration, and MG-specific treatment are similar to another large MG study in Germany [30]. Although we included the main known influencing factors, such as age, sex, disease severity, and comorbidities, in the matching, we cannot exclude the risk of residual bias in propensity score matching. Moreover, we have not included the auto-antibody status in our risk analysis, which potentially could have an impact on COVID-19 disease course due to differences in immune response [52, 54]. Additionally, we cannot exclude a reporting bias for hospitalized and severe cases for patients with MG included in our study, although we minimized the risk by our multicentric approach. Due to the small numbers of COVID-19-affected patients with MG in the IST subgroups, we cannot draw conclusions about the risk with the single IST, which especially accounts for rituximab. We were unable to include data on IST used in the past, IST dosage, and duration of ongoing IST before infection in our analysis. We also did not collect data on social or economic factors (e.g., employed or retired) that could potentially influence virus exposure. Future studies with a larger number of patients with MG and COVID-19 are strongly needed to confirm our results and, in particular, to clarify questions regarding the impact of different immunosuppressant therapies.

Conclusions

This registry-based cohort study suggests that the current use of IST does not increase the risk of SARS-CoV-2 infection per se but, together with older age, worsens the prognosis of COVID-19-affected patients with MG. Nevertheless, corticosteroid monotherapy was not a relevant risk factor for COVID-19 severity in our study. Our data indirectly support the consequent implementation of vaccination strategies, such as early booster vaccination, especially in patients with MG treated with IST to effectively prevent COVID-19 in this high-risk group. Further studies with larger patient populations are strongly needed to better understand the risk and consequences of individual immunosuppressant subgroups for patients with MG, while the COVID-19 pandemic persists.

Acknowledgements This work is dedicated to the memory of Hans Rohn (1951–2021), who, as chairman of the German Myasthenia Society, championed the interests of patients and made possible the establishment of the German Myasthenia Registry. We thank our coworkers of the NeuroCure Clinical Research Center at the Charité Universitätsmedizin Berlin, especially Norbert Baro for data management and administrative work of the MyaReg, and Claudia Heibutzki, Dike Remstedt, Marret Heinold, Stephanie Marschens, and Sandra Lischewski for administration support. Additionally, we thank Klaus Baumgartner, Jan-Frederik Marx, and Nina Budelmann from the Institute for Quality and Patient Safety (BQS) for the technical support of the databank and data management. The authors thank all participating patients and the German Myasthenia gravis Society for supporting the German Myasthenia gravis Registry.

Author contributions Conceptualization: FS and AM. Methodology: FS, AM, and UG. Formal analysis: UG. Data acquisition: all authors. Writing—original draft preparation: FS and AM. Writing—review and editing: SH, PM, MS, TR, FB, JK, US, ADM, AT, TH, CJ, BB, PPU, KCK, BH, DL, PK, MP, and HW. Supervision: AM.

Funding Open Access funding enabled and organized by Projekt DEAL. The German Myasthenia gravis Registry was established with the resources of the German Myasthenia gravis Society (grant number not applicable) and received financial support from Alexion Pharma (grant number not applicable). PM is Einstein Junior Fellow funded by the Einstein Foundation Berlin and has been supported by the grants from the Bundesministerium für Bildung und Forschung (Grant No. 16GW0191 and NUM-COVID-19 –Organo-Strat 01KX2021).
Availability of data and materials The study was conducted in accordance to the Declaration of Helsinki and the STROBE reporting guidelines.

Code availability Not applicable.

Declarations

Conflicts of interest F. Stascheit received speaker honoraria from Alexion. U. Grittner reports no conflict of interest, S. Hoffmann received speaker honoraria from Alexion. P. Mengenthaler receives funding from the Einstein Foundation Berlin, and is supported by grants from the Bundesministerium für Bildung und Forschung, the Volkswagen Foundation, and the Else Kröner Fresenius Stiftung, and is on the board of HealthNextGen Inc. and has equity interest in the company. M. Schroeter reports speaker honoraria from Argenx, Bayer, Biogen, Datamed, Grifols, Merck, Roche, Sanofi. He received consulting fees from Alexion, Biogen, Argenx/Effran MG, Gilead, and Roche. T. Ruck reports grants from German Ministry of Education, Science, Research and Technology, grants and personal fees from Sanofi-Genzyme, Novartis and Alexion; personal fees from AbbVie, argnx, Biogen, Bristol-Myers Squibb, Roche and Teva; personal fees and nonfinancial support from Merck Serono, outside the submitted work. F. Blaes received speaker honoraria from UCB, Argenx and Grifols. J. Kaiser reports no conflicts of interests. U. Schara received speaker honoraria from Alexion and Biogen. A. D. Marina reports no conflicts of interest. T. Hagenacker reports speaker honoraria from Alexion, argnx and Hormsosan, Biogen, Roche Sanofi Genzyme and Novartis Gene Therapies. He received consulting fees from Biogen, Roche, Sanofi Genzyme, Alexion, argnx, Hormsosan and Alnylam and research support from Sanofi Genzyme, Roche, Biogen and Novartis. C. Jacobi reports speaker honoraria from Alexion, CSL Behring, TEVA and Sanofi Genzyme. He received consulting fees from Alexion, Roche, Merck Serono and Novartis. P. P. Urban received speaker honoraria from Alexion. B. Berger received travel grants and/or training expenses from Bayer Vital GmbH, Ipsen Pharma GmbH, Novartis, Biogen GmbH and Genzyme, as well as lecture fees from Ipsen Pharma GmbH, Alexion Pharma GmbH, Merck, Sanofi Genzyme and Roche. K. C. Knop received speaker honoraria from Alexion, Bayer, Biogen, Grifols, Hormsosan, Novartis, Sanofi Genzyme, Roche and consulting fees from Hormsosan, Merck, Sanofi Genzyme and Sarepta. B. Schalk received consulting fees from argnx. D. J. Lee received speaking honoraria from Alexion, Anylam, Biogen, Janssen, Merck, Novartis, Roche and Sanofi. P. Kalischewski received speaker honoraria, consulting fees and NIS from Biogen, Sanofi, Teva, Merck, Roche, Novartis and Biogen. M. Pavlitzki received speaker honoraria and travel/accommodation/meeting expenses from Novartis. H. Wiendl is acting as a paid consultant for Abbvie, Actelion, Biogen, IGES, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis, and the Swiss Multiple Sclerosis Society. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, the European Union, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children’s Foundation, Biogen, GlaxoSmithKline GmbH, Roche Pharma AG, Sanofi-Genzyme. A. Meisel received speaker honoraria, consulting fees or financial research support from Alexion, argnx, Grifols, Hormsosan, Janssen, Octapharmam UCB and Vitaccess for consulting services and financial research support from Octapharma and Alexion. He serves as chairman of the medical advisory board of the German Myasthenia Gravis Society.

Ethical statement The study was conducted in accordance to the Declaration of Helsinki and the STROBE reporting guidelines and was registered at the WHO-licensed German clinical trial registry (DRKS00024099). The study was approved by the ethics committee of the Charité-Universitätsmedizin Berlin (EA1/025/11).

Consent to participate Informed consent was obtained from all individual participants included in the study.

Consent for publication All authors have approved the manuscript for submission; accordingly, the manuscript conforms to the journal’s policies. The authors take full responsibility for the data, the analyses and interpretation, and the conduct of the research. They have full access to all data, and the right to publish any and all data separate and apart from the guidance of any sponsor.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Abbas AS, Hardy N, Ghozy S, Dibas M, Paranjape G, Evanson KW, Reierson NL, Cowie K, Kamrowski S, Schmidt S, Tang Y, Davis AR, Touchette JC, Kallmes KM, Hassan AE, Tarchand R, Mehta M, Pederson JM, Abeldeimeegd M (2022) Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: a systematic review. Clin Neurol Neurosurg 213:107140
2. Anand P, Slami MCC, Kakau M, Ong C, Cervantes-Arasian LM, Zhou L, David WS, Guidon AC (2020) COVID-19 in patients with myasthenia gravis. Muscle Nerve 62:254–258
3. Amann D, Heming N, Grimaldi-Bensouda L, Frémeaux-Bacchi V, Vigan M, Roux AL, Marchal A, Michelon H, Rottman M, Moine P (2020) Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. EClinicalMedicine 28:100590
4. Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150–161
5. Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Marotte H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A, Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Filpo RM, Richez C (2021) COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 3(6):e419–e426. https://doi.org/10.1016/S2665-9913(21)00059-X
6. Businaro P, Vaghi G, Marchioni E, Diamanti L, Arceri S, Bini P, Colombo E, Cosentino G, Alfonsi E, Costa A, Ravaglia S, Malucci G, Ballante E, Franciotta D, Gastaldi M (2021) COVID-19
in patients with myasthenia gravis: epidemiology and disease course. Muscle Nerve 64:206–211
7. Buszko M, Park JH, Verthelyi D, Sen R, Young HA, Rosenberg AS (2020) The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nat Immunol 21:1146–1151
8. Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendonça RH, Souza PVS, Pinto W, Oliveira ASB, Dangoni-Filho I, Pouza AFP, Valerio BCO, Zanotelli E (2020) Myasthenia Gravis and COVID-19: clinical characteristics and outcomes. Front Neurol 11:1053
9. Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragazzino A, De Negri P, Di Gennaro C, Pagano A, Alleggerico E, Bressy L, Bosso G, Ferrara A, Serra C, Montisci A, D’Amico M, Schiano Lo Morello S, Di Costanzo G, Tucci AG, Marchetti P, Di Vincenzo U, Sorrentino I, Casciotta A, Fusco M, Buonerba C, Berretta M, Ceccarelli M, Nunnari G, Diessa Y, Cicala S, Facchini G (2020) Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL. Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24:4040–4047
10. Gadjos P, Chevret S, Toyka KV (2012) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 12:Cd002277
11. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang HL, Cao YY, Yan Q, Cao C, Gao HY, Bruigén MC, van de Veen W, Sokolowska M, Akdis M, Akdis CA (2021) Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76:428–455
12. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzaninis IG, Psaltopoulou T, Kastritis E, Terpos E, Dimopoulou MA (2021) Emerging treatment strategies for COVID-19 infection. Clin Exp Med 21:167–179
13. Gianfrancesco M, Hyrich KL, Adeloye S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF, Ruff S, Schmaju G, Simonard J, Strangfeld A, Trupin L, Wysam KD, Bhana S, Costello W, Grainger R, Hall E, Imai K, King G, Stuart EA (2011) MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 1(8):2011
14. Ho D, Imai K, King G, Stuart EA (2011) MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 8(1):2011
15. Hasselaar R, Hokelohu U, Yoon J (2005) The R Package ggeopp for generalized estimating equations. J Stat Softw 1(2):2006
16. Horby P, Lim WS, Emberson JR, Mathieu M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmhøj E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Justczak E, Baille Ker, Haynes R, Landray MJ (2021) Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 384:693–704
32. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Pielch F, Frissell T (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77:184–191

33. Mantegazza R, Cavalcante P (2019) Diagnosis and treatment of myasthenia gravis. Curr Opin Rheumatol 31(6):623–633

34. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 395:1033–1034

35. Melzer N, Ruck T, Fuhr P, Gold R, Holifeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendel H (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 263:1473–1494

36. Muppudi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, Tavee JO, Kaminski H, Howard JF Jr, Cutter G, Wiendl H, Maas MB, Illa I, Mantegazza R, Muri H, Utsugisawa K, Nowak RJ (2020) COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol 19:970–971

37. Nelke C, Stascheit F, Eckert C, Pavlikitz M, Schroeter CB, Hunte M, Nagowski M, Mengenthaler P, Arat E, Oztkur M, Foell D, Schreiber S, Vielhaber S, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Wiendl H, Ruck T (2022) Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflamm 19:89

38. Neumann B, Angstwurm K, Mengenthaler P, Kohler S, Schonenberger S, Boseli J, Neumann U, Vidal A, Huttner HB, Gerner ST, Thieme A, Steinbrecher A, Dunkel J, Roth C, Schneider H, Schimmel E, Fuhrer H, Fahrendorf C, Alberty A, Zinke J, Meisel A, Dohmen C, Stetefeld HR (2020) Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology 94:e299–e313

39. Neumann B, Angstwurm K, Mengenthaler P, Kohler S, Schonenberger S, Boseli J, Neumann U, Vidal A, Huttner HB, Gerner ST, Thieme A, Steinbrecher A, Dunkel J, Roth C, Schneider H, Schimmel E, Fuhrer H, Fahrendorf C, Alberty A, Zinke J, Meisel A, Dohmen C, Stetefeld HR (2020) Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology 94:e299–e313

40. Raiker R, DeYoung R, Pakchanian H, Ahmed S, Cavalcante P, Gupta L, Kardeš S (2021) Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States. Semin Arthritis Rheum 51:1057–1066

41. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson PC, Yazdany J, Jacobsohn L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Izadi Z, Jacobsohn L, Katz P, Kearse-Fleet L, Robinson PC, Tazdany J, Machado PM (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89:780–789

42. Sharifi-an-Dorchê M, Sahraian MA, Fadda G, Osherov M, Sharif-ian-Dorchê A, Karaminia M, Saveriano AW, La Piana R, Antel JP, Giacomini PS (2021) COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review. Mult Scler Relat Disord 50:102800

43. Siemieniuk RA, Bartoszko JJ, Diaz Martinez JP, Küm E, Qasim A, Zeraikatar D, Iczovich A, Mangala S, Ge L, Han MA, Agorsits T, Arnold D, Avila C, Chu DK, Coban R, Cusano E, Darzi AJ, Devji T, Foroutan F, Ghadimi M, Khamis A, Lamontagne F, Loeb M, Miroshnychenko A, Motaghi S, Murthy S, Mustafa RA, Rada G, Rochweg B, Switzer C, Vandyk PO, Vermeij RW, Wang Y, Yao L, Guyatt GH, Brigardello-Petersen R (2021) Antibody and cellular therapies for treatment of COVID-19: a living systematic review and network meta-analysis. BMJ 374:n2231

44. Solé G, Mathis S, Friedman D, Salort-Campana E, Tard C, Bouhuoy F, Magot A, Annane D, Blair C, Le Masson G, Sourlages A, Duval F, Carla L, Violeau MH, Saulnier T, Segovia-Kuensy S, Kern L, Antoiné JC, Beaudonnet G, Audic F, Kremer L, Chanson JB, Nadaj-Pakleza A, Stoikovic T, Cintas P, Spinazzi M, Foubert-Samier A, Attarian S (2021) Impact of coronavirus disease 2019 on a French cohort of myasthenia gravis. Neurology 96:e2109–e2120

45. Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89:780–789

46. Sterner JAC, Murthy S, Diaz JV, Slutsksy AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emerson J, Fisher D, Giraudureau B, Gordon AC, Grahnholm A, Green C, Haynes R, Heming N, Higgin JPT, Horpy P, Jüni P, Landray MJ, Le Gouge A, Leclere M, Lim WS, Machado FR, McArthur C, Meziane F, Möller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC (2020) Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324:1330–1341

47. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Lijung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scirè CA, Siroth E, Sparks JA, Sufka P, Thomas T, Trupin L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Ildzi Z, Jacobsohn L, Katz P, Kearse-Fleet L, Robinson PC, Tazdany J, Machado PM (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80:930–942

48. Team RC (2021): R: A language and environment for statistical computing. In, https://www.R-project.org/

49. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M (2020) COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 50:620–632

50. Uzawa A, Kwabara S, Suzuki S, Imae T, Murai H, Ozawa Y, Yasuda M, Nagane Y, Utsugisawa K (2020) Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Curr Opin Rheumatol 31(6):623–633

51. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M (2020) COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 50:620–632

52. Uzawa A, Kwabara S, Suzuki S, Imae T, Murai H, Ozawa Y, Yasuda M, Nagane Y, Utsugisawa K (2020) Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Curr Opin Rheumatol 31(6):623–633

53. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang Z, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180:934–943

54. Yi JS, Guptill JT, Statthopoulos P, Nowak RJ, O’Connor KC (2018) B cells in the pathophysiology of myasthenia gravis. Muscle Nerve 57:172–184
